Prinomastat Explained

Prinomastat (code name AG-3340) is a matrix metalloproteinase (MMP) inhibitor with specific selectivity for MMPs 2, 3, 9, 13, and 14. Investigations have been carried out to determine whether the inhibition of these MMPs is able to block tumour metastasis by preventing MMP degradation of the extracellular matrix proteins and angiogenesis. Prinomastat underwent a Phase III trial to investigate its effectiveness against non-small cell lung cancer (NSCLC), in combination with gemcitabine chemotherapy. However, it was discovered that Prinomastat did not improve the outcome of chemotherapy in advanced non-small-cell lung cancer.[1] [2]

Notes and References

  1. Bissett D, O'Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA . 6 . Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer . Journal of Clinical Oncology . 23 . 4 . 842–849 . February 2005 . 15681529 . 10.1200/JCO.2005.03.170 . free .
  2. Hande KR, Collier M, Paradiso L, Stuart-Smith J, Dixon M, Clendeninn N, Yeun G, Alberti D, Binger K, Wilding G . 6 . Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor . Clinical Cancer Research . 10 . 3 . 909–915 . February 2004 . 14871966 . 10.1158/1078-0432.CCR-0981-3 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Prinomastat".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.